Hoth Therapeutics Partners with OnTargetx R&D to Advance Research for Cancer fighting HT-KIT Cancer Therapeutic

Core Insights - Hoth Therapeutics, Inc. has announced a collaboration with OnTargetx R&D Inc. to advance research for its cancer-fighting therapeutic, HT-KIT, marking a significant step in its preclinical development [1][3] - The study focuses on the development and optimization of staining methods for c-Kit markers, which are critical to the therapeutic mechanism of HT-KIT [2] - HT-KIT is a preclinical therapeutic candidate targeting c-Kit, a receptor tyrosine kinase involved in various cancers, representing a potential advancement in precision oncology therapies [3] Company Overview - Hoth Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing innovative and impactful treatments aimed at improving patient quality of life [4] - The company emphasizes a patient-centric approach and collaborates with scientists, clinicians, and key opinion leaders to explore therapeutics with significant potential [4]